Jakavi (Ruxolitinib)

Ruxolitinib blocks the activity of Janus kinase 1 and 2 (JAK1/JAK2), key enzymes in the JAK‑STAT signaling cascade. By inhibiting these kinases, the drug reduces phosphorylation of STAT proteins, leading to decreased transcription of cytokine‑driven genes that promote abnormal cell growth and inflammation in the targeted diseases.

The appropriate dose of Jakavi is individualized by the prescribing clinician based on the specific indication, patient weight, blood counts, liver and kidney function, and any concomitant medications. Dosage adjustments may be required over time to maintain efficacy while minimizing toxicity.

Safety data for ruxolitinib in pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be ruled out, Jakavi is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk.

To request Jakavi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and the necessary import documentation.

Jakavi (ruxolitinib) is a first‑generation JAK1/JAK2 inhibitor, whereas other agents such as fedratinib target JAK2 more selectively. Clinical choice often depends on the specific disease, prior therapy, side‑effect profile, and patient comorbidities. Jakavi has a well‑established efficacy record in myelofibrosis and polycythemia vera, while newer agents may offer alternative dosing or safety considerations.

Jakavi tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep the medication in its original blister pack, protect it from moisture and direct sunlight, and store it out of reach of children.

Jakavi is taken orally as a tablet. Patients should swallow the tablet whole with water; it may be taken with or without food. The exact timing and frequency are determined by the prescriber and should be followed exactly as instructed.

The most serious adverse events include severe or opportunistic infections, significant cytopenias such as anemia and thrombocytopenia, and hepatic toxicity manifested by elevated liver enzymes. Patients should be monitored closely for signs of infection, bleeding, or liver dysfunction throughout therapy.

Jakavi is contraindicated in individuals with known hypersensitivity to ruxolitinib or any tablet excipients. It should also be avoided in patients with active severe infections, uncontrolled liver disease, or those who are pregnant. Clinicians must evaluate each patient’s medical history before initiating therapy.